Eline

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Eline

Property Description
Active ingredient Metoclopramide hydrochloride
Form Tablet, Oral Solution, Injection, Suppository
Pharmacological class Prokinetic agent, Antiemetic
General Purpose Enhancing GI motility and controlling sickness
Origin Synthetic compound

Eline: Definition and Pharmacological Classification

Eline is a single-ingredient, prescription-only medicine whose fundamental nature is defined by its active ingredient, Metoclopramide hydrochloride. It is primarily classified as a Prokinetic agent and a systemic Antiemetic. This drug belongs chemically to the Benzamide derivative family, confirming its origin as a synthetic compound designed to act on the Gastrointestinal system. Metoclopramide maintains an established role in clinical practice for the management of various motility disorders.

What Forms and Substance Types Define Eline?

The medication is supplied across several essential pharmaceutical preparations to ensure flexible and effective delivery. These include standard Tablets, a liquid Oral solution, and concentrated Solution for injection (for Intravenous or Intramuscular routes), in addition to Suppositories. The compound's composition involves the Metoclopramide active substance alongside standard solid excipients or an aqueous solution base. The availability of the Oral solution form allows for precise dose adjustments, making it a valuable choice for patient groups where swallowing tablets may be difficult.

General Purpose and Core Therapeutic Benefit of Eline

The core therapeutic benefit of Eline is to provide comprehensive relief by both enhancing digestive movement and simultaneously suppressing the body's emetic signals. Its function as a Prokinetic agent increases GI motility, ensuring food passes through the stomach more efficiently, while its powerful Antiemetic action directly controls the urge to vomit. Clinically, the medication is recognized for its use in managing conditions characterized by delayed stomach emptying and controlling the symptoms of nausea and vomiting.

Regulatory References

  1. Metoclopramide - StatPearls - NCBI Bookshelf
  2. Metoclopramide-containing medicines - referral

What side effects are possible with Eline?

Possible Side Effects and Safety Information

The safety profile of Eline is based on official government regulatory documents (such as those from the EMA and FDA), which categorize and classify adverse reactions and establish limitations on use.


Adverse Reaction Scope

The known side effects, or adverse reactions, are grouped by the body system they affect and classified according to their frequency:

Frequency Classification Estimated Incidence
Very Common Occurs in 1 out of 10 people or more.
Common Occurs in 1 to less than 10 out of 100 people.
Uncommon Occurs in 1 to less than 10 out of 1,000 people.
Rare Occurs in 1 to less than 10 out of 10,000 people.
Very Rare Occurs in less than 1 out of 10,000 people.
Not Known Cannot be estimated from available data (often post-marketing reports).

Side effects are organized across established regulatory categories, including Infections and infestations, Nervous system disorders, Gastrointestinal disorders, Skin and subcutaneous tissue disorders, and General disorders and administration site conditions.


Critical Safety Considerations

Serious Adverse Reactions (SARs): Regulatory labels explicitly document serious adverse reactions that may require immediate medical attention or lead to significant outcomes. These can include life-threatening events, instances of severe organ toxicity, and events subject to a Boxed Warning if deemed necessary by the regulating authority.

Safety-Related Restrictions: Eline has specific Contraindications, which are conditions where the medicine must not be used (e.g., severe hypersensitivity to the drug, specific pre-existing organ failure). The official documents also contain Precautions and Warnings outlining circumstances that require special caution or monitoring, such as use in patients with a history of certain medical conditions or concurrent use with specific other medications.

Population-Specific Safety: Special warnings and required modifications are documented for use in specific populations, including considerations for patients who are pregnant or breastfeeding, or those with renal (kidney) or hepatic (liver) impairment, based on known risks documented in the official prescribing information.

Overdose and Emergency Response

Documented Overdose Manifestations

Overdose of Eline (Metoclopramide hydrochloride) is documented in regulatory labeling with a specific set of manifestations. Overexposure may present with Central Nervous System (CNS) effects, including drowsiness, confusion, disorientation, and lethargy (lack of energy). A key documented sign is the presence of extrapyramidal reactions (EPS), which involves involuntary, uncontrollable movements or acute dystonic reactions, as well as seizures and diarrhea. Symptoms are generally defined as self-limiting and often resolve within 24 hours, but immediate medical assessment is mandatory due to the risk of severe complications.

Severe Outcomes and Emergency Actions

Regulators list severe outcomes such as Neuroleptic Malignant Syndrome (NMS) and life-threatening cardiovascular events, including circulatory collapse and cardiac arrest. A serious hematologic risk is Methemoglobinemia, which is particularly noted in neonates following overexposure.

Mandated Emergency Action: Immediate medical help must be sought for any suspected overdose. Emergency services (e.g., 911) must be contacted immediately if the individual experiences seizures, collapse, trouble breathing, or inability to be awakened. Treatment is symptomatic and supportive, as no specific compound antidote is known for general overdosage. However, methylene blue is documented to reverse Methemoglobinemia, and anticholinergic agents may be used for EPS control. Specific warnings are noted regarding infants and children, who face heightened risks of EPS and Methemoglobinemia.

Therapeutic Uses of Eline

Eline is commonly used to help with specific conditions and symptoms related to heightened physiological activity. This medicine is relevant for managing sickness. The medication is applied when symptoms related to physical discomfort, such as nausea and vomiting, become more disruptive during acute clinical events, including the postoperative period or during chemotherapy and radiotherapy sessions. This supportive benefit helps ease the overall symptom burden, supporting patients during difficult episodes by easing distress.


The therapeutic domain of Eline is relevant across therapeutic areas involving acute, symptomatic episodes or chronic functional stress. Relevant areas include the symptomatic management of Diabetic Gastroparesis, symptomatic relief of sickness associated with acute migraine attacks, and supportive symptom management of postoperative sickness. The medication offers therapeutic support for conditions presenting with systemic or localized discomfort characterized by impaired movement in the upper digestive tract. It is considered relevant in situations where symptoms cluster into patterns of postprandial fullness, bloating, and chronic epigastric discomfort linked to organ-specific functional stress.

“Eline provides supportive relief that helps patients cope more steadily with symptom fluctuations, assisting with general well-being during symptomatic phases.”

Quick Fact: Relief for Gastric Stasis Symptoms

Quick Fact: Relief for Gastric Stasis Symptoms Eline helps maintain a sense of stability by assisting with the functional movement of the stomach, contributing to improved day-to-day comfort in patients dealing with motility disorders.

Regulatory References

  1. U.S. National Library of Medicine DailyMed

Eligibility and Restrictions for Use

Who Can and Cannot Use Eline? (Metoclopramide)

The eligibility profile for Eline is strictly defined by regulatory authorities based on age, medical history, and specific comorbidities.

Contraindicated Populations

Eline is contraindicated (must not be used) in patients with specific conditions, including a known history of epilepsy or seizure disorder, pheochromocytoma, or severe gastrointestinal issues like hemorrhage, mechanical obstruction, or perforation. It is also contraindicated in patients with a history of tardive dyskinesia or severe extrapyramidal reactions related to metoclopramide, as well as in children under one year of age.


Eligibility Restrictions and Conditional Use

Population Group Regulatory Condition
Organ Impairment Patients with moderate to severe renal or hepatic impairment require mandatory dosage reduction.
Age Limits Use is not recommended for chronic use exceeding 12 weeks for any patient. Use in children 1 year is restricted to specific, limited indications (e.g., secondary use for post-chemotherapy sickness). Older adults may require a lower starting dosage.
Comorbidities Caution is required for patients with Parkinson's disease or a history of depression.
Reproductive Status Use during pregnancy and lactation is generally restricted or not recommended, requiring careful assessment due to the drug crossing the placental barrier and passing into breast milk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for Eline (Metoclopramide hydrochloride) defines specific drug combinations that are restricted or prohibited, and notes conditions that affect drug exposure. This profile is structured around pharmacokinetic and pharmacodynamic interactions as documented by regulatory authorities.

Formal Restrictions and Interaction Outcomes

Classification Interacting Agents Officially Documented Outcome
Contraindicated Levodopa or Dopaminergic Agonists Mutual antagonism (Pharmacodynamic interaction)
Additive Risk CNS Depressants (including alcohol) Potentiation of sedative effects
Additive Risk Neuroleptics, EPS-Inducing Drugs Increased risk of Extrapyramidal Disorders (EPS)
Exposure Change Strong CYP2D6 Inhibitors (e.g., Fluoxetine) Increased Eline systemic exposure
Absorption Effect Cyclosporine Eline increases Cyclosporine bioavailability

Population and Timing Constraints

The prokinetic action of Eline can modify the absorption of co-administered oral medicines, such as decreasing Digoxin bioavailability or enhancing Aspirin absorption. The combination with Serotonergic Drugs is officially noted to increase the risk of Serotonin Syndrome. For safe administration, a minimal interval of 6 hours between any two doses of Eline is mandated to avoid accumulation. Furthermore, Renal and Severe Hepatic Impairment as well as being a CYP2D6 Poor Metabolizer are documented physiological factors that lead to reduced drug clearance and higher systemic concentrations.

Mechanism of Action

Modulation of Receptor-Mediated Signaling

Eline acts within biological domains involving receptor-mediated signaling by selectively engaging specific membrane receptors. These receptors are key components in systems where neurotransmitters or other circulating mediators dominate pathway activity. This engagement initiates a signaling sequence that modifies early molecular steps, thereby limiting the intracellular impact of excessive mediator activity within targeted pathways.

Regulation of Enzyme-Driven Cascades

The drug influences biological processes where targeted pathway adjustment is required by modulating enzyme-mediated cascades. Eline selectively modifies the activity of a critical metabolic enzyme, which shapes the overall systemic physiological outcomes. This mechanism contributes to stabilizing processes that are overactive or dysregulated at the cellular level.

Facilitation of Feedback Regulation

Eline engages mechanisms that influence feedback regulation within signaling pathways, particularly in contexts involving rapid modulation of physiological responses. This engagement facilitates a more regulated state within the targeted biological systems, leading to predictable physiological adjustments and shaping the overall pharmacodynamic effect profile of the drug.

Dosage and Administration Information

Eline (Metoclopramide hydrochloride) is officially administered via multiple routes, including Oral (tablets or solution), Intravenous (IV), Intramuscular (IM), and Rectal (suppositories). The parenteral forms (IV/IM) are generally intended for the shortest possible duration, with a procedural expectation of switching to the oral or rectal route as quickly as feasible.

For adults, the standard single dose is 10 mg. Clinical guidelines define specific daily limits; for example, the total daily dose for diabetic gastroparesis is generally limited to 40 mg. Oral administration is typically scheduled four times daily (QID) and must be timed 30 minutes before meals and at bedtime. A critical constraint across all forms is the minimum 6-hour interval that must be maintained between any two administrations.

The duration of use is subject to clinical limitations. For acute symptomatic conditions, usage is typically restricted to a maximum of 5 consecutive days. Longer courses, such as those for diabetic gastroparesis, are generally confined to 2 to 8 weeks. Furthermore, dose adjustments are mandatory for certain patient populations; the dose must be reduced by 50% or more in patients with moderate to severe renal impairment to adhere to the official use protocol.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Eline

The research for Eline (Metoclopramide) was studied for various acute and functional gastrointestinal contexts. This overview is limited to describing what the research has studied and reported, and what remains uncertain, based on authoritative regulatory and scientific sources.


Research Evidence for Managing Diabetic Gastroparesis

This section summarizes the structure of short-term, placebo-controlled trials that have explored research exploring how symptoms change over time in adults with delayed gastric emptying due to diabetes.

The study designs observed short-term treatment durations, typically up to 12 weeks. Research examined patient-reported outcomes describing perceived discomfort, such as the frequency of vomiting and feelings of early satiety, as well as objective measures like how quickly food empties from the stomach. The populations included adults with documented diabetes and delayed gastric emptying.

Findings describe patterns observed in the studies related to measured symptom changes and measured gastric function. Research describes that outcomes were measured over defined time intervals. This means that results apply only to the populations studied and the specific short durations examined.

What remains uncertain: There is limited information for long-term outcomes or the effect of continuous use beyond the short-term study periods. The research does not determine whether an individual will respond similarly over extended periods.


Research for Acute Nausea and Vomiting

This part focuses on the Randomized Controlled Trials (RCTs) and Systematic Reviews that have evaluated Eline's use in two primary acute settings: the prevention of sickness after surgery and the management of symptoms during acute migraine attacks.

Studies for Postoperative Sickness

Multiple RCTs and systematic reviews have explored Eline's use in patients immediately following surgical procedures. Studies monitored outcomes related to physical discomfort, specifically the incidence and severity of nausea and vomiting in the 24 hours after surgery. Research also examined the need for rescue anti-sickness medications. The volume of evidence provides insight into short-term changes in this acute setting, with findings describe patterns observed in the studies comparing Eline to placebo or other anti-sickness agents. Comparative evidence with other anti-sickness agents is part of the research landscape.

Studies for Acute Migraine-Associated Sickness

Research in this area has utilized RCTs, with studies primarily utilizing the parenteral (injection) route of administration in adults presenting with acute migraine attacks. Studies were conducted during research exploring short-term symptom changes and examined changes in headache pain intensity and associated outcomes related to systemic or functional imbalance, such as nausea. Research highlights changes measured during the study period, assessed at acute time points. Findings describe that the research base is strongly tied to the parenteral administration route in acute clinical settings.


Evidence in Specific, Restricted Clinical Situations

This section reviews the structure of evidence for situations where Eline's use is limited or restricted, including the prevention of delayed sickness following chemotherapy and the management of refractory Gastroesophageal Reflux Disease (GERD) in adults.

Evidence for Delayed Sickness After Chemotherapy

Comparative trials research examined Eline's role in managing nausea and vomiting that manifests a day or more after chemotherapy. This evidence contributes to the broader evidence landscape. Studies monitored outcomes describing episodic or acute changes in symptoms following different chemotherapy regimens. Data show patterns related to measured symptom changes, but comparative evidence is lacking against the most modern anti-sickness treatments, and the research for this scenario often utilized regimens considered high-dose.

Review of Evidence for GERD in Adults and Infants

  • Adult Refractory GERD: Studies explored Eline's use in adults with GERD whose symptoms persisted despite trying other medications. Research focused on patient-reported outcomes describing perceived discomfort (e.g., heartburn) over short study durations, typically less than three months. Regulatory reviews noted that evidence for prolonged treatment in this context is insufficient to support its continued use.

  • Infant GERD: Studies exploring Eline in infants (under two years of age) focused on outcomes such as symptom frequency and feeding tolerance. However, evidence quality varies across studies, and many are small. As a result, certainty remains low, and the research provides insufficient data for confident guidance on widespread use in this age group.


Long-Term Studies and Duration of Use

Clinical trials for Eline in most approved indications are designed to evaluate research exploring short-term symptom changes and are generally limited in their follow-up durations. The majority of evidence reflects observations over periods of days to weeks. There is limited information for long-term outcomes and continued use for chronic conditions. Long-term use is not supported by the available evidence base. Research does not determine whether an individual will respond similarly over extended periods.


Evidence in Special Populations and Research Gaps

Studies have been conducted to evaluate Eline's use in children (aged one year and older) for specific conditions. Research has explored short-term changes in these groups, but studies evaluating treatment choices are complex and varied.

Overall, subgroup findings are uncertain for many specialized populations. Key research gaps documented by regulators and scientific reviews include:

  • The limited information for long-term outcomes across all conditions.
  • Sample sizes were modest in some key studies for chronic conditions.
  • Comparative evidence is lacking in certain scenarios when compared against newer treatment standards.
  • Data for certain groups, such as very young children, remain insufficient.
  • Research highlights what is known—and what is still uncertain—about Eline's use in conditions associated with acute or disruptive episodes.

Key Studies & References

  1. A multicenter placebo-controlled clinical trial of oral metoclopramide in diabetic gastroparesis
  2. Metoclopramide for nausea and vomiting prophylaxis during and after Caesarean delivery: a systematic review and meta-analysis
  3. Acute medicines for migraine (Metoclopramide as anti-sickness medicine and short-term use limits)

Frequently Asked Questions (FAQ)

Common questions about Eline (FAQ)

Q: Are there any common interactions between Eline and herbal supplements?

Official drug safety documents list known interactions with prescription medicines, over-the-counter medicines, and alcohol. However, official regulatory information generally does not list specific interactions with common herbal or plant-based supplements. Information regarding any concurrent use of herbal products should be shared with a healthcare professional.

Q: Is Eline safe to use if I have high blood pressure?

Official documents state that caution is required when Eline is used in patients with high blood pressure. The medication is strictly prohibited for use in patients with a specific condition called pheochromocytoma, which is a rare tumor related to high blood pressure. All conditions must be reviewed by a healthcare provider before starting treatment.

Q: Can Eline affect my sleep pattern?

Official documents classify side effects like drowsiness and lassitude (a feeling of weariness or lack of energy) as common effects. These nervous system effects are recognized as potentially affecting a person's normal sleep or rest patterns. Sleepiness is also listed as a common effect.

Q: Does Eline interact with caffeine or alcohol?

Official regulatory documents state that alcohol should be avoided because it may worsen central nervous system side effects, such as sleepiness. Information regarding a specific interaction with caffeine is not typically provided in regulatory sources. Any consumption of caffeine is a topic to review with a healthcare professional.

Q: Is Eline safe for elderly patients?

Official information notes that older adults are more likely to experience certain side effects, particularly movement disorders such as tardive dyskinesia, and drowsiness. Due to possible age-related changes in kidney function, a lower starting dosage may be required. Careful assessment and monitoring are typically advised for older adults.

Q: Can Eline be used during pregnancy or while breastfeeding?

Regulatory bodies advise that Eline should only be used during pregnancy if the potential benefit clearly justifies the potential risk, based on a healthcare professional's risk assessment. Regulatory documents describe that the drug passes into breast milk in small amounts, and short-term use has been reviewed in this context.

Q: Is Eline affected by certain foods or meals?

Official administration instructions state that oral forms of Eline, such as tablets or solution, should be taken 30 minutes before meals. This specific timing is required to help ensure the medication is properly absorbed and can begin acting on the stomach before food is introduced.

Q: Does Eline interact with common pain relievers like ibuprofen?

Regulatory documents note that Eline can alter the absorption of some oral medicines, such as Digoxin and Aspirin. However, official sources do not typically list a direct interaction with the common pain reliever ibuprofen. Providing a full list of all concurrent medications to a healthcare professional is standard procedure.

Q: Why does Eline have a warning label about [A serious safety topic]? (e.g., liver risk)

Eline carries a serious safety warning (a Boxed Warning in the US) regarding the risk of a serious, potentially irreversible movement disorder called Tardive Dyskinesia (TD). Regulatory labels also document rare cases of hepatotoxicity (liver damage), especially when used alongside other liver-affecting drugs.

Q: Does Eline have any long-term monitoring requirements, like blood tests?

While on Eline, patients are advised to be monitored for signs of serious movement disorders (TD/EPS) and for severe depression. Official guidance also requires dose adjustments for those with renal (kidney) or hepatic (liver) impairment, which may necessitate specific laboratory tests to check organ function.

Q: Do you feel different when you first start taking Eline?

The start of treatment with Eline can sometimes cause common nervous system side effects such as drowsiness, restlessness, or tiredness. These initial feelings are generally described in official sources as typically mild and temporary as the body adjusts to the medicine.

Q: Is it common to feel tired or dizzy while on Eline?

Tiredness (fatigue/lassitude) and drowsiness are listed in regulatory documents as common side effects. Dizziness or lightheadedness may also occur and is considered a common effect. These symptoms are usually temporary.

Q: Is Eline available over the counter in any country?

Eline is classified as a prescription-only medicine in the countries governed by the major global regulatory authorities, including the United States, Europe, and Canada. It is not generally available over the counter.

Q: Are there different strengths or dosages of Eline available?

Eline is available in multiple strengths and forms to allow for flexibility in administration. These typically include 5 mg and 10 mg tablets, as well as an oral solution, and an injection form for clinical use.

Q: Why is Eline sometimes discontinued by users?

Official documents advise that Eline must be stopped immediately if a patient develops certain serious side effects. These include the movement disorder Tardive Dyskinesia (TD), Neuroleptic Malignant Syndrome, or severe depression.

Q: What is the typical duration of treatment with Eline?

Treatment with Eline is restricted to short periods. For most acute conditions, usage is typically limited to a maximum of 5 consecutive days. For chronic conditions, such as diabetic gastroparesis, treatment is generally limited to a maximum of 8 to 12 weeks.

Q: Are the effects of Eline permanent after stopping the medicine?

Regulatory documents caution that the serious movement disorder known as Tardive Dyskinesia (TD), which may be caused by Eline, is often described as potentially irreversible (permanent) even after the medication is discontinued. This is why strict duration limits apply to its use.

Q: Are there genetic factors that might affect how Eline works for me?

Official information notes that certain genetic factors can affect how the body processes Eline. For example, individuals classified as CYP2D6 Poor Metabolizers have reduced drug clearance, which can lead to higher levels in the body and an increased risk of side effects.

Q: Is there a specific diet recommended while taking Eline?

Official guidance states that, aside from avoiding alcohol, a person can generally eat and drink normally while taking Eline. The main instruction concerning food is the requirement to take the dose 30 minutes before meals.

Q: Is it normal to feel anxious after starting Eline?

Regulatory documents list a range of nervous system and psychiatric effects as possible, including restlessness and low mood/depression. While the term 'anxiety' is not always explicitly used, these related common effects are part of the reported safety profile when initiating treatment.

How should Eline be stored and disposed of?

How to Store and Dispose of Eline (Metoclopramide) Officially

Storage and disposal of Eline must adhere strictly to the conditions specified in the official labeling to maintain product stability and ensure safety.


Official Storage Requirements

Condition Requirement
Temperature Store at Controlled Room Temperature, 20 C to 25 C (68 F to 77 F), with permitted excursions up to 30 C (86 F).
Protection Protect from light and moisture. The product must be kept from freezing and stored away from excess heat.
Container Keep the medication in the container it came in, tightly closed.
Child Safety Must be kept out of the sight and reach of children.

Official Disposal Instructions

Unused or expired Eline should be disposed of using a drug take-back program. If a program is not available, the product must be mixed with an undesirable substance, sealed, and placed in the trash; do not flush Eline down the toilet. This procedure ensures proper pharmaceutical waste management.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Eline found in:

A-Z Index: